Immunic investor relations
Witryna25 kwi 2024 · Immunic, Inc. Jessica Breu Head of Investor Relations and Communications +49 89 2080 477 09 [email protected]. US IR Contact Rx … Witryna1 wrz 2024 · Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, and Jessica Breu, Head of Investor Relations and Communications at Immunic, will …
Immunic investor relations
Did you know?
WitrynaM.A. Business Management Student, Investor Relations and PR at Immunic Therapeutics Metropolregion München. 95 Follower:innen … Witryna3 lis 2024 · Immunic, Inc. Jessica Breu Head of Investor Relations and Communications +49 89 2080 477 09 [email protected]. US IR Contact Rx …
Witryna3 sie 2024 · --Immunic, Inc., a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced ... Witryna31 gru 2024 · Results of Operations. The Company reported a net loss of $41.5 million for the year ended December 31, 2024, which compared with a net loss of $52.1 million for the prior year. This resulted in a net loss of $0.98 per share for the year ended December 31, 2024, as compared to a net loss of $1.31 per share for 2024, on both a …
Witryna3 lis 2024 · Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release. Contact Information. Immunic, Inc. Jessica Breu Head of Investor Relations and Communications +49 89 2080 477 09 [email protected]. US IR Contact Rx Communications Group … WitrynaInvestor updates. Past IR events View all events. Investors. 2024 Credit Suisse Global Healthcare Conference. Read more. Investors. ... Investor relations team contacts. Genentech. Genentech has been delivering on the promise of biotechnology for over 35 years. Discover more. Contact. Locations.
Witryna1 wrz 2024 · Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune ...
Witryna13 kwi 2024 · Immunic Inc (NASDAQ:IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC). Vitt describes it as "wonderful data" that came as a "positive … ims storageWitryna23 sie 2024 · Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. ... Head of Investor Relations and Communications. Standort. Größere Karte. Gräfelfing. Lochhamer Schlag 21, 82166 … lithography crayonWitryna10 paź 2024 · Immunic, Inc. Jessica Breu Head of Investor Relations and Communications +49 89 2080 477 09 [email protected]. Rx Communications … ims strategic incomeWitryna5 kwi 2024 · Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and … ims streamingWitryna14 mar 2024 · Seed-Investment des HTGF: Münchner Startup oculai schließt 2,5 Mio. € Seed-Runde zur KI-gestützten Prozesserfassung auf Baustellen ab ... Parcellab, Cobrainer, Quantum Systems, Casavi, Riskmethods, Tubulis, Catalym, Immunic, Sirion und viele weitere. ... Stefanie Grüter, Partner Communications & Relations T.: +49 … lithography cycleWitrynaWednesday, June 16, 2024 10:00 AM EDT. Eyenovia Inc. First Quarter 2024 Earnings Call. Wednesday, May 12, 2024 4:30 PM EDT. Eyenovia Inc. Fourth Quarter 2024 Earnings Call. Thursday, March 25, 2024 4:30 PM EDT. 33rd Annual Roth Conference. Monday, March 15 - Wednesday, March 17, 2024. ims strasbourgWitryna14 lip 2024 · NEW YORK, July 14, 2024 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX ), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies ... ims student login mits gwalior